Next Gen Immuno-Oncology Congress MarketsandMarkets

June 21-22, 2018

Philadelphia - USA

The next big question in cancer immunotherapy is what’s next in immuneoncology?
Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.

Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors

The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiomederived immunotherapy and new paradigms in immune checkpoint inhibitors.
Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
With more than 35+ speakers at the congress, they will focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in celluar and viral therapies, vaccines development and personalized immunotherapy.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

 

Register for our 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress 2020, write an email to [email protected]

ENQUIRE NOW

CONFERENCE SPEAKERS

ADVISORS

Stefan Glueck

Stefan Glueck

Senior Vice President, Global Medical Affairs, Celgene

Roy Baynes

Roy Baynes

Executive Vice President, Chief Medical Officer, Eikon Therapeutics

John Delaney

John Delaney

Executive Director, Research, Amgen

SPEAKERS

Eytan Barnea

Eytan Barnea

Founder and Chief Scientist, BioIncept LLC

Ellen Pure

Ellen Pure

Professor and Chair, Department of Biomedical Sciences, University of Pennsylvania

Terry Fisher

Terry Fisher

Director, Translational Science and Bioanalytical, Vaccinex

Judi Wardwell-Swanson

Judi Wardwell-Swanson

Senior Application Scientist, Insphero

Pirouz Daftarian

Pirouz Daftarian

Senior Manager, Applications for Immunooncology and Vaccines , JSR Micro Life Sciences and MBL International

Raj Chavali

Raj Chavali

Senior Director, Caris Lifesciences

Joost Oppenheim

Joost Oppenheim

Head, Cellular Immunology, NIH

Christophe Queva

Christophe Queva

Chief Scientific Officer, Oncorus

Ashok Shrivastava

Ashok Shrivastava

CEO, Cure Pharmaceuticals

Mark Gardner

Mark Gardner

CEO, OmniSeq

Patrick Hanley

Patrick Hanley

Director, GMP for Immunotherapy, Assistant Professor, Children’s National Medical Centre

Frank Walsh

Frank Walsh

CEO, Ossianix Inc.

SPONSORS

Lonza
PBL Assay Science
Mitra Biotech
Advanced Cell Diagnostics
Caris Life Sciences
InSphero
Cytek
Nebion
MBL International Corporation
ACEA Biosciences
MedGenome Inc
Studylog
STEMCELL Technologies
Ossianix

PARTNERS

LOCATION

Venue

Philadelphia - USA

PAST EVENT GALLERY